# Adalimumab for the Management of Post-operative Crohn's Disease (CD)

> **NCT01629628** · PHASE3 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** 6 Mercaptopurine

## Key facts

- **NCT ID:** NCT01629628
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2012-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01629628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01629628, "Adalimumab for the Management of Post-operative Crohn's Disease (CD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01629628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*